Clinical Study

Phase 1/2, Two-Part, Open-Label Dose-Escalation And Double-Blind, Placebo-Controlled Dose-Expansion Study With An Open-Label Extension To Evaluate The Safety And Efficacy Of Ata188 In Subjects With Progressive Multiple Sclerosis

Posted Date: Jun 22, 2021

  • Investigator: Aram Zabeti
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

This is a multicenter, 2-part study in adult subjects with progressive forms of MS with an open-label, single-arm sequential dose-escalation period (Part 1) and a double-blind, randomized, placebo-controlled dose-expansion period (Part 2) and OLE, both of which may be initiated at the sponsor’s discretion, based on a review of data from the dose-escalation cohorts. This study will evaluate the safety and efficacy of ATA188 administered by intravenous (IV) infusion.


Participant Must Be Between 18-66 And Have A History Of Progressive Form Of Ms (Ppms Or Spms).


Progressive Multiple Sclerosis, Neurology, Ms

For More Information:

Tiffany Rupert

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.